Gamunex®-C

Understanding Gamunex-C®

Gamunex-C® is an immune globulin (IgG) therapy used to treat Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Immune Thrombocytopenic Purpura (ITP). It helps strengthen the immune system in patients with immunodeficiency and modulates the immune response in autoimmune conditions. Gamunex-C® is available as both intravenous (IVIG) and subcutaneous (SCIG) infusions, offering flexible administration options for patients.

How Gamunex-C® Works:

• Provides IgG antibodies to support immune function.
• Helps prevent infections in immunodeficient patients.
• Modulates immune response in autoimmune conditions like CIDP and ITP.

FDA Approval:

• December 10, 2003 – Approved for the treatment of Primary Immunodeficiency (PI) and Immune Thrombocytopenic Purpura (ITP)
• 2008 – Expanded approval to include Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

For more information, please visit the Gamunex-C® patient website and speak with your healthcare provider to determine if Gamunex-C® is the right treatment option for you.